![]() Tumor thrombus beyond the portal vein range, such as hepatic vein, inferior vena cava, right atrium, splenic vein, superior mesenteric vein cancer thrombus, etc.Patients who have received liver transplantation in the past.Those with a known history of central nervous system metastasis or hepatic encephalopathy.Severe allergic reaction to other monoclonal antibodies.The number of system treatment lines ≥ 2 lines.The patient is using immunosuppressive agents or systemic hormone therapy to achieve the purpose of immunosuppression (dose>10mg/day prednisone or other curative hormones), and continues to use it within 2 weeks before enrollment.The patient has any active autoimmune disease or a history of autoimmune disease.Non-surgical sterilization or female patients of childbearing age need to use a medically approved contraceptive method (such as an intrauterine device, contraceptive, or condom) during the study treatment period and within 3 months after the end of the study treatment period Female patients of childbearing age who undergo surgical sterilization must be negative in serum or urine HCG within 72 hours before enrollment in the study and must be non-lactating for male patients whose partners are women of childbearing age, at the last time use effective methods for contraception within 3 months.The absolute count of neutrophils≥1.5×109/L Platelet ≥50×109/L Hemoglobin ≥60 g/L Serum albumin ≥28 g/L Thyroid-stimulating hormone (TSH)≤1×ULN (if abnormal, the levels of FT3 and FT4 should be examined at the same time, if the levels of FT3 and FT4 are normal, they can be included in the group) Bilirubin≤2×ULN (within 7 days before the first administration) ALT and AST ≤5×ULN (within 7 days before the first dose) Serum creatinine≤1.5×ULN.The functions of vital organs meet the following requirements (no blood components, cell growth factors and other corrective treatment drugs are allowed within 14 days before the first administration):.Newly diagnosed patients who have not received targeted therapy or immunotherapy in the past.BCLC-C stage accompanied by tumor thrombosis-associated portal hypertension.Clinically diagnosed or pathologically confirmed hepatocellular carcinoma, at least one measurable focus without local treatment (according to mRECIST requirements, the measurable focus spiral CT scan length ≥ 10 mm or enlargement Short diameter of lymph node ≥15 mm).≥18 and ≤ 75 years old, both male and female.The patient voluntarily joined the study and signed an informed consent form.Why Should I Register and Submit Results?.Goshen Hospital Emergency Department uses leading-edge technology to diagnose and treat blood clots in the arm in Goshen, IN. We’re dedicated to keeping your blood flowing as it should, whether that’s with emergency care or preventive screenings. Staying active to keep your blood flowing is one of the best defenses against blood clots. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |